No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALKS Alkermes
- 23.760
- -0.250-1.04%
Close Apr 18 16:00 ET
- 23.280
- -0.480-2.02%
Post 16:50 ET
4.02BMarket Cap11.31P/E (TTM)
24.140High23.620Low1.80MVolume23.860Open24.010Pre Close42.86MTurnover1.12%Turnover Ratio11.31P/E (Static)169.18MShares33.71052wk High3.34P/B3.82BFloat Cap22.01052wk Low--Dividend TTM160.79MShs Float98.500Historical High--Div YieldTTM2.17%Amplitude3.550Historical Low23.827Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Alkermes to Report First Quarter Financial Results on May 1, 2024
DUBLIN, April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Hold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory Challenges
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Comments
Nancy S. Lurker's appointment to Alkermes' Board is viewed positively, bringing deep industry experience and commercial expertise. Her broad skills are expected to drive growth of existing products, portfolio expansion, and new product launches.
Press Release: Alkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsAlkermes' surplus of cash over debt and its ability to convert EBIT to free cash flow indicate a conservative balance sheet and low risk in its debt management.
Although Alkermes' share price has recently dipped, its long-term business trends are positive. Insider purchases, often seen as a good omen by investors, add further optimism.
$Alkermes(ALKS.US$ huge call options in dec, unusual. buyout for JPM healthcare conference next week?
ColumnsToday's pre-market stock movers: ANGO, SKIL, CXM, HPQ and more
Gainers:
• $AngioDynamics(ANGO.US$ +13.5%, $Skillsoft(SKIL.US$ +3.26%, $Sprinklr(CXM.US$ +8.96%, $Cazoo(CZOO.US$ +11.1%, $Apogee Enterprises(APOG.US$ +3.3%, $Levi Strauss & Co.(LEVI.US$ +1.7%, $Constellation Brands(STZ.US$ + 0.8%
• $Momentus(MNTS.US$ +36.9% (signed multiple launch agreements with Space Exploration Technologies Corp)
• $HP Inc(HPQ.US$ +10.1% (Berkshire Hathaway's Warren Buffett disclosed the purchase of mln sh...
• $AngioDynamics(ANGO.US$ +13.5%, $Skillsoft(SKIL.US$ +3.26%, $Sprinklr(CXM.US$ +8.96%, $Cazoo(CZOO.US$ +11.1%, $Apogee Enterprises(APOG.US$ +3.3%, $Levi Strauss & Co.(LEVI.US$ +1.7%, $Constellation Brands(STZ.US$ + 0.8%
• $Momentus(MNTS.US$ +36.9% (signed multiple launch agreements with Space Exploration Technologies Corp)
• $HP Inc(HPQ.US$ +10.1% (Berkshire Hathaway's Warren Buffett disclosed the purchase of mln sh...
15
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg